[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 29, Issue 6 (1-2022) ::
Journal of Ilam University of Medical Sciences 2022, 29(6): 36-47 Back to browse issues page
Evaluation of the Effect of Liposome Carriers and Albumin Nanoparticles Containing Activated Melittin on Inhibiting the Growth of Leishmania Major Amastigote in vivo
Soheila Akhzari1 , Sedigheh Nabian * 2, Parviz Shayan1 , Mohammad Taheri3
1- Dept of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
2- Dept of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran , Nabian@ut.ac.ir
3- Rastegar Reference Laboratory, School of Veterinary Medicine, University of Tehran, Tehran, Iran
Abstract:   (1348 Views)
Introduction: Leishmaniasis is an infectious and parasitic disease that is among the most important zoonotic diseases in tropical and subtropical regions, as well as developing countries. Despite the efforts of clinical researchers over the years, few signs of progress have been made in the treatment of cutaneous leishmaniasis leading to satisfactory clinical improvement. In this study, activated melittin was used to treat leishmaniasis caused by Leishmania major. Moreover, liposomes and nanoparticles of albumin were used separately for the entry of myelin into leishmania-infected macrophages. Furthermore, their effects on Leishmania-infected cells were compared in vivo.
Material & Methods: After designing activated melittin peptide for a selective expression using pep fold and expasy servers, liposomes and albumin nanoparticles were used to transfer the peptide into the cell and evaluate the function of transfer vectors on Leishmania major-infected cells. Finally, they were investigated in vivo to analyze the anti-leishmaniasis activity of carriers containing activated melittin and their uptake by macrophages.
(Ethic code: 7506009/6/35)
Findings After wounding the BALB/c mice on the second week, an effective concentration of 100 μl of each of the nanoparticles of albumin and liposome containing 25 μg of activated melittin was injected into BALB/c mice as a therapeutic dose. After the fifth week, in the third group (control), the wound size increased significantly and eventually led to the death of the mice in the control group. However, in the first and second groups treated with liposomes containing peptide and nanoparticle albumin, at the beginning of the fifth week, the wound size got smaller, and the recovery process initiated (P<0.05).
Discussion & Conclusion: The results of this part of the study showed that the therapeutic effects with liposome carriers and albumin nanoparticles containing 25 μg/ml activated melittin in mice with leishmaniasis can be compared with those of the control group. Liposome and nanoparticle carriers of albumin-containing activated melittin have been suggested as an effective, appropriate, and even alternative treatment for cutaneous leishmaniasis.
Keywords: Albumin nanoparticles, Leishmania major, Liposomes, Melittin
Full-Text [PDF 817 kb]   (568 Downloads)    
Type of Study: Applicable | Subject: medical parasitology
Received: 2021/05/9 | Accepted: 2021/09/18 | Published: 2022/02/4
1. Akhzari S, Rezvan H, Zolhavarieh SM, Moafi M. Comparison of proinflammatory gene expression in lesions caused by either burn injuries or cutaneous Leishmaniasis. Gene Cell Tis2017;4: 81-6. doi.10.17795/gct-42887.
2. Cummings HE, Tuladhar R, Satoskar AR. Cytokines and their STATs in cutaneous and visceral leishmaniasis. J Biomed Biotechnol2010; 2:23-7. doi.10.1155/2010/294389
3. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chem 2004;53:158-66. doi.10.1093/jac/dkh058.
4. Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, et al. Leishmaniasis treatment a challenge that remains: a review. Parasitol Res2008;103:41-6. doi.10.1007/s00436-008-0943-2.
5. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure function and biochemistry. Circul Res2003;92:827-39. doi.10.1161/01.RES.0000070112.80711.3D.
6. Mast BA, Schultz GS. Interactions of cytokines, growth factors and proteases in acute and chronic wounds. Wound Rep Reg1996;4:411-20. doi.10.1046/j.1524-475X.1996.40404.x.
7. Ravindran R, Bhowmick S, Das A, Ali N. Comparison of BCG and MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral Leishmaniasis. BMC Microbiol 2010;10:1-7. doi.147-2180/10/181.
8. Adade CM, Oliveira IR, Pais JA, Soutopadrón T. Melittin peptide kills Trypanosoma cruzi parasites by inducing different cell death pathways. Toxicon2013; 69:227-39. doi.10.1016/j.toxicon.2013.03.011.
9. Wade D, Boman A, Wahlin B, Drain CM, Andreu D, Boman HG, et al. All di amino acid containing channel forming antibiotic peptides. Proce Nat Acad Sci1990 J;87:4761-5. doi. 10.1073/pnas.87.12.4761.
10. BAzzo R, Tappin MJ, Pastore A, Harvey TS, Carver JA, Campbell ID. The structure of melittin a 1H NMR study in methanol. European J Biochem1988 ;173:139-46. doi.10.1111/j.1432-1033.1988.tb13977.x.
11. Tichy J, Novak J. Detection of antimicrobials in bee products with activity against viridans streptococci. J Alt Comple Med 2000;6:383-9. doi.10.1089/acm.2000.6.383
12. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Int Biol 2009;1:382-93. doi.10.1039/b904890a.
13. Marettimira AC, Pinho KM, Oliveira MP, Pirmez C, Craft N. MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. Actatropica 2011;119:160-4. doi.10.1016/j.actatropica.2011.05.009.
14. Tirkey, Bulbul, Bharatbhushan, S. Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti proliferative effects of suicide gene therapy. Mate Sci Eng 2017;73: 507-15. doi.10.1016/j.msec.2016.12.108
15. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Int Biol2009;1:382-93. doi.10.1039/b904890a.
16. Lainson R, Shaw JJ. Evolution classification and geographical distribution. 1th ed. Academic Publication.1987;P.213-23.
17. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis drugs in the clinic resistance and new developments. Drug Res Up 2004;7:257-66. doi.10.1016/j.drup.2004.07.002.
18. Croft SL, Sundar S, Fairlamb AH. Drug resistance in Leishmaniasis. Clin Microbiol Rev 2006;19:111-26. doi.10.1128/CMR.19.1.111-126.2006
19. Croft SL, Yardley V. Chemotherapy of Leishmaniasis. Cur Pharm Des2002;8:319-42. doi.10.2174/1381612023396258.
20. Maleki MA, Javidi Z, Taheri AR, Ebrahimi Rad M, Rasti MA. A study of hematologic, hepatic and renal side effects of intramuscular injection of meglumine antimoniate on patients with cutaneous leishmaniasis. Med J Mashhad Uni Med Sci2007;50:371-8. doi.10.22038/MJMS.2007.5555
21. Zhang L, Falla TJ. Host defense peptides for use as potential therapeutics. Cur Opin Inv Drug 2009;
22. 10:164-71.doi.10.1007/978-1-60761-594-1_19.
23. Moghimipour E, Aghel N, Mahmoudabadi AZ, Ramezani Z, Handali S. Preparation and characterization of liposomes containing essential oil of Eucalyptus camaldulensis leaf. Jundishapur J Natural Pharm Prod 2012;7:117. doi.10.5812/jjpharma.5261.
24. Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous Leishmaniasis. J Lip Res 2010;20:16-23. doi. 10.3109/08982100903015025.
25. Jithan AV, Madhavi K, Madhavi M, Prabhakar K. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. International journal of pharmaceutical investigation. 2011 1:119. doi.10.4103/2230-973X.82432.
26. Pereira AV, Barros GD, Pinto EG, Tempone AG, Orsi RD, Santos LD, et al. Melittin induces in vitro death of Leishmania infantum by triggering the cellular innate immune response. J Ven Anim Tox Includ Trop Dis 2016;22:63-7. doi.10.1186/s40409-016-0055-x
27. Eltahirsaeed WS, Gasimkhalil EA. Immune response modifying effects of bee venom protein melittin autoclaved L.donovani complex in CD1 Mice the search for new vaccine adjuvants. J Vac 2017;8:2. doi.10.4172/2157-7560.1000372.
28. Khalili S, Mohebali M, Ebrahimzadeh E, Shayan E, Mohammadiyeganeh S, Moghaddam MM, et al. Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major. Vet Res Forum 2018 ;9: 323. doi.10.30466/vrf.2018.33107.
29. Borborema SE, Schwendener RA, Junior JA, Andrade HF, Nascimento N. Uptake and antileishmanial activity of meglumine antimoniate containing liposomes in Leishmania major infected macrophages. Int J Antimicrobial Age 2011;38:341-7. doi.10.1016/j.ijantimicag.2011.05.012
30. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, Andrade HF. Targeting Leishmania chagasi amastigotes through macrophage scavenger receptors the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chem 2004 ;54:54-9. doi.10.1093/jac/dkh281
Send email to the article author

Add your comments about this article
Your username or Email:


Ethics code: 7506009/6/35

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akhzari S, Nabian S, Shayan P, Taheri M. Evaluation of the Effect of Liposome Carriers and Albumin Nanoparticles Containing Activated Melittin on Inhibiting the Growth of Leishmania Major Amastigote in vivo. J. Ilam Uni. Med. Sci. 2022; 29 (6) :36-47
URL: http://sjimu.medilam.ac.ir/article-1-7091-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 29, Issue 6 (1-2022) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4646